bortezomib

0:11:41

Found in Translation: The Tale of the Cancer Drug Bortezomib (Velcade)

0:03:53

Proteasome inhibitor drugs

0:07:05

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

0:01:36

Bortezomib and dexamethasone after ASCT for high-risk MM

0:16:11

All About Velcade (Bortezomib) for Myeloma patients #myeloma

0:00:16

BORVIZ 2 MG (BORTEZOMIB INJECTION 2MG #science #nursing #medicalstudent #doctor #pharmacist

0:02:06

Once-weekly bortezomib dosing as SoC in multiple myeloma: an international survey of physicians

0:01:32

Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma

0:00:43

The impact of bortezomib dose adjustment in the OPTIMISMM study

0:02:40

OPTIMAL: bortezomib-based therapy vs thalidomide-based therapy in myeloma with renal failure

0:02:06

Novel Anti-Cancer Agents for Multiple Myeloma

0:00:50

The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMM

0:02:55

Daratumumab + bortezomib, melphalan, and prednisone vs bortezomib, melphalan, and prednisone for MM

0:44:44

2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy

0:03:00

Bortezomib-based triplet regimens in MM patients undergoing transplantation

0:01:01

High-risk multiple myeloma vs standard-risk myeloma: what’s the difference? (In a minute or less)

0:02:53

Real-world data on upfront subcutaneous bortezomib-containing regimens for newly diagnosed myeloma

0:02:00

Combining bortezomib and lenalidomide-based regimens for frontline MM

0:01:25

Real world data: bortezomib-based therapy for R/R myeloma

0:13:13

Velcade (Bortezomib) Explained: What Myeloma Patients Need to Know

0:01:34

Myeloma: pomalidomide, bortezomib and dexamethasone

0:57:14

Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer Institute

0:01:45

Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in HR-SMM

0:08:02

Bortezomib (Velcade) Mechanism of Action - Proteosome Inhibitors